VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Pathogen Page
Marburg Virus

Table of Contents

  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
    4. Microbial Pathogenesis
    5. Host Ranges and Animal Models
    6. Host Protective Immunity
  2. Vaccine Related Pathogen Genes
    1. 26S mRNA from VEEV
    2. GP
    3. GP from Angola Marburg Virus
    4. GP from Marburg virus Ci67
    5. GP from Marburg virus Ravn
    6. GP from Marburgvirus
    7. GP from Musoke Marburgvirus
    8. GP from Zaire ebolavirus
    9. GP protein [Marburg marburgvirus]
    10. GP Sudan ebolavirus
    11. Lassa nucleoprotein
    12. NP
    13. NP from Lake Victoria marburgvirus
    14. NP from Marburg virus Musoke
    15. NP from Marburgvirus Ravn
    16. NP from Tai Forest Ebolavirus
    17. NP from Zaire ebolavirus
    18. PagA from Bacillus anthracis
    19. SGP
    20. VP24
    21. VP30
    22. VP35
    23. VP40
  3. Vaccine Information
    1. Adenovirus vectors expressing Marburg virus glycoprotein
    2. CAdVa-Filoviruses (EbMarburg viruses)
    3. cAdVaxM(fus)
    4. Heterologous MARV Protein VLP
    5. Irradiated MBGV antigen
    6. Marburg virus DNA prime/boost vaccine DNA/rAd5-GP encoding GP from strain Angola
    7. Marburg virus DNA vaccine DNA-GP encoding GP
    8. Marburg virus DNA vaccine MARV GP encoding GP
    9. Marburg virus glycoprotein expressed by baculovirus recombinants
    10. Marburg Virus Nucleoprotein Vaccine
    11. Marburg virus recombinant vector vaccine CAdVax-Panfilo
    12. Marburg virus recombinant vector vaccine MBGV GP
    13. Marburg virus recombinant vector vaccine MBGV GP/MBGV NP
    14. Marburg Virus Vaccine Ad26.Filo, MVA-BN-Filo
    15. Marburg Virus Vaccine mVLP Poly I:C Adjuvant
    16. Marburg Virus Vaccine mVLP QS-21 Adjuvant
    17. Marburg Virus Vaccine PHV01
    18. Marburg Virus Vaccine pVAKS-GPVM
    19. Marburg Virus Vaccine rVSV-N4CT1-MARV-GP
    20. Marburg virus-like particles
    21. Multivalent DNA vaccine for B. anthracis, Ebola virus, Marburg virus, and VEE virus
    22. Recombinant VEE Replicons expressing MBGV GP
    23. Recombinant VEE Replicons expressing MBGV NP
    24. VSV-based vaccine expressing MBGV GP
  4. References
I. General Information
1. NCBI Taxonomy ID:
186537
2. Disease:
Hemorrhagic fever
3. Introduction
Marburg was identified in 1967 in Central Africa. It has been known to infect bats, humans, and non-human primates. The virus has caused severe outbreaks of, usually, fatal hemorrhagic fever. In primates, the symtoms are known to be fever, diarrhea, vomiting, coagulation deficits, and severe liver damage. The virus causes a profuse release of inflammatory cytokines, which affects vascular permeability. The excessive bleeding involved sometimes leads to the activation of tissue factor in macrophages and monocytes, as well as a drop in platlet numbers (Mohamadzadeh et al., 2007).
4. Microbial Pathogenesis
The initial targets of infection are generally macrophages, monocytes, and DCs. Filoviruses generally bind to the TREM or C-type lectin receptors on myloid cells. However, since some cells do not express C-lectin or TREM receptors, viral entry may be due to molecules such as heparin-sulphate proteoglycan and folate receptor-α. Data also indicate that the expression of TLR1 (whose signal converges with that of TLR2) was increased on MARV-activated neutrophils (Mohamadzadeh et al., 2007).
5. Host Ranges and Animal Models
The natural host for MARV is known to be bats of Central African origin (Mohamadzadeh et al., 2007).
6. Host Protective Immunity
Filoviruses have been found to disable some of the host IFN pathway, such as the VP35, which prevents the production of type I IFNs, and VP24, which interferes with the abilities of certain molecules to induce antiviral states. IFN is crucial to immune response, as indicated by elevated levels of IFN in the blood even during acute infection. It had also been seen that there is a deficit (virus-induced) in the co-stimulatory properties of infected Dcs, identified by a supressed capacity of the DCs to stimulate allogenic T cells. By affecting either viral exit or entry, cellular proteases could influence viral cellular tropisms and interactions between antibodies and glycoproteins. All host protective immunity observations are also tied with the prevalence of an abundance of cathepsins (Mohamadzadeh et al., 2007).
Loading...
Loading Pathogen Genes...
Loading...
Loading Host Genes...
Loading...
Loading Vaccines...
Loading References...